|Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA||CEO & Pres||1.97M||N/A||1969|
|Mr. Matthew Donald Dallas||Sr. VP & CFO||899.86k||N/A||1975|
|Ms. Hanne Heidenheim Bak||Sr. Project Director, R&D Operations Mang. and Employee Representative Director||21.11k||N/A||1953|
|Mr. Adam Sinding Steensberg M.D.||Exec. VP of R&D and Chief Medical Officer||1.17M||N/A||1974|
|Mr. Ivan Mourits MÃ¸ller||Sr. VP of Technical Devel. & Operations||N/A||N/A||1972|
|Ms. Rie Schultz Hansen||VP of Discovery & Innovation||N/A||N/A||N/A|
|Lani Pollworth Morvan||Investor Relations & Communications Officer||N/A||N/A||N/A|
|Mr. Mads Kronborg||Head of Investor Relations & Communication||N/A||N/A||N/A|
|SÃ¸ren Vitfell Keller||Head of Legal Affairs||N/A||N/A||N/A|
|Mr. Marino Garcia M.B.A.||Sr. VP of Corp. & Bus. Devel.||N/A||N/A||1966|
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S’s ISS governance QualityScore as of 1 July 2021 is 1. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 1; Compensation: 1.